Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001437749-22-005570
Filing Date
2022-03-08
Accepted
2022-03-08 17:14:46
Documents
15
Period of Report
2022-02-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K/A cbli20220308_8ka.htm   iXBRL 8-K/A 27631
2 EXHIBIT 99.1 ex_344678.htm EX-99.1 13906
7 sb01.jpg GRAPHIC 6407
  Complete submission text file 0001437749-22-005570.txt   191617

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA stab-20220222.xsd EX-101.SCH 3600
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE stab-20220222_def.xml EX-101.DEF 11903
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE stab-20220222_lab.xml EX-101.LAB 15928
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE stab-20220222_pre.xml EX-101.PRE 12114
9 EXTRACTED XBRL INSTANCE DOCUMENT cbli20220308_8ka_htm.xml XML 2698
Mailing Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526
Business Address 2537 RESEARCH BOULEVARD, SUITE 201 FORT COLLINS CO 80526 (888) 613-8802
Statera Biopharma, Inc. (Filer) CIK: 0001318641 (see all company filings)

EIN.: 200077155 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-32954 | Film No.: 22722718
SIC: 2834 Pharmaceutical Preparations